Gsk3B — Glycogen Synthase Kinase 3 Beta is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Symbol | GSK3B |
|---|
| Full Name | Glycogen Synthase Kinase 3 Beta |
|---|
| Chromosomal Location | 3q13.33 |
|---|
| NCBI Gene ID | 2932 |
|---|
| OMIM | 605004 |
|---|
| Ensembl ID | ENSG00000082701 |
|---|
| UniProt ID | P49841 |
|---|
| Protein | GSK3B Protein |
|---|
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Bipolar Disorder |
|---|
GSK3B (Glycogen Synthase Kinase 3 Beta) is a serine/threonine-protein kinase that plays a central role in neuronal function, synaptic plasticity, and the pathogenesis of neurodegenerative diseases. It is one of the most studied tau kinases and is implicated in Alzheimer's disease through its ability to hyperphosphorylate tau protein, leading to neurofibrillary tangle formation.
GSK3B is a multifunctional kinase involved in numerous cellular signaling pathways:
- Tau phosphorylation: GSK3B is one of the primary kinases responsible for phosphorylating tau protein at multiple sites (Ser199, Ser202, Thr205, Ser212, Ser396, Ser404), regulating its ability to bind microtubules[1]
- Wnt signaling: GSK3B is a key component of the Wnt/β-catenin pathway, where it phosphorylates β-catenin targeting it for degradation[2]
- Glycogen metabolism: Originally identified as a regulator of glycogen synthase, hence its name
- Synaptic plasticity: GSK3B regulates NMDA receptor trafficking, AMPA receptor internalization, and long-term potentiation (LTP)[3]
- Gene transcription: Modulates transcription factor activity including CREB, NF-κB, and p53
- Apoptosis: Regulates pro-apoptotic and anti-apoptotic pathways in neurons
- Circadian rhythm: Influences circadian clock gene expression
GSK3B is widely expressed throughout the brain with high levels in:
- Hippocampus (CA1-CA3 pyramidal neurons)
- Cerebral cortex (layer V pyramidal neurons)
- Cerebellum (Purkinje cells)
- Substantia nigra (dopaminergic neurons)
- Basal forebrain cholinergic neurons
Both GSK3α and GSK3β isoforms exist, with GSK3B being the brain-enriched isoform.
GSK3B is centrally implicated in AD pathogenesis:
- Tau hyperphosphorylation: Elevated GSK3B activity leads to excessive tau phosphorylation at AD-relevant sites, promoting NFT formation[4]
- Aβ interaction: Amyloid-beta peptide activates GSK3B, creating a vicious cycle between Aβ accumulation and tau pathology
- Synaptic dysfunction: GSK3B overactivity contributes to synaptic loss through AMPA receptor internalization
- Neuroinflammation: GSK3B regulates pro-inflammatory cytokine production in microglia
- Therapeutic target: GSK3B inhibitors have been investigated for AD treatment
- α-Synuclein phosphorylation: GSK3B phosphorylates α-synuclein at Ser129, promoting its aggregation[5]
- Dopaminergic neuron survival: GSK3B activity influences dopaminergic neuron viability
- Mitochondrial dysfunction: Interacts with PINK1/Parkin pathway
- LRRK2 interaction: G2019S LRRK2 mutation enhances GSK3B activity
¶ Bipolar Disorder and Mood Disorders
- GSK3B polymorphisms associated with bipolar disorder susceptibility
- Lithium directly inhibits GSK3B, explaining its mood-stabilizing effects[6]
- GSK3B regulates circadian rhythms disrupted in mood disorders
- Stroke: Neuroprotective effects of GSK3B inhibition
- Amyotrophic Lateral Sclerosis: Altered GSK3B signaling in motor neurons
- Huntington's Disease: Dysregulated GSK3B activity
GSK3B is a major drug target for neurodegenerative diseases:
| Drug/Compound |
Mechanism |
Status |
| Lithium |
Direct GSK3B inhibitor |
Approved for bipolar disorder |
| Tideglusib |
Non-ATP competitive inhibitor |
Clinical trials for AD/PSP |
| AR-A014418 |
ATP-competitive inhibitor |
Preclinical |
| VP0.7 |
Natural compound inhibitor |
Preclinical |
| TDZD-8 |
Thiadiazolidinone inhibitor |
Preclinical |
Challenges: Pan-GSK3 inhibition affects glucose metabolism; isoform-selective inhibitors are needed.
- Mandelkow EM, et al. (1992). Tau protein, function and pathology. Prog Mol Subcell Biol. PMID:1285014
- Grimes CA, Jope RE (2001). The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Prog Neurobiol. PMID:11243779
- Hooper C, et al. (2008). The GSK3 hypothesis of Alzheimer's disease. J Neurochem. PMID:18088381
- Avila J, et al. (2010). GSK3B and tau phosphorylation in Alzheimer's disease. J Alzheimer's Dis. PMID:20061641
- Yuan YH, et al. (2019). GSK3B and α-synuclein in Parkinson's disease. Brain Res Bull. PMID:30552873
- Li X, et al. (2002). Lithium suppresses tau pathology by modifying the activity of GSK3β in vivo. J Mol Neurosci. PMID:11988080
The study of Gsk3B — Glycogen Synthase Kinase 3 Beta has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Mandelkow EM, et al. (1992). "Tau protein, function and pathology." Progress in Molecular and Subcellular Biology. PMID:1285014
- Grimes CA, Jope RE (2001). "The multifaceted roles of glycogen synthase kinase 3 beta in cellular signaling." Progress in Neurobiology. PMID:11243779
- Hooper C, et al. (2008). "The GSK3 hypothesis of Alzheimer's disease." Journal of Neurochemistry. PMID:18088381
- Avila J, et al. (2010). " GSK3 beta and tau phosphorylation in Alzheimer's disease." Journal of Alzheimer's Disease. PMID:20061641
- Yuan YH, et al. (2019). "GSK3 beta and alpha-synuclein in Parkinson's disease." Brain Research Bulletin. PMID:30552873
- Li X, et al. (2002). "Lithium suppresses tau pathology by modifying the activity of GSK3 beta in vivo." Journal of Molecular Neuroscience. PMID:11988080
- Hernandez F, et al. (2013). "GSK3 beta and tau protein: A dangerous liaison in Alzheimer's disease." ACS Chemical Neuroscience. PMID:23578187
- Hanger DP, et al. (2009). "Novel phosphorylation sites in tau from Alzheimer brain support the role of GSK3 beta in disease progression." Journal of Alzheimer's Disease. PMID:19190889
- Takashima A (2006). "GSK-3 is essential in the pathogenesis of Alzheimer's disease." Journal of Alzheimer's Disease. PMID:16952250
- Hooper C, et al. (2007). "GSK3 alpha/beta in the pathogenesis and therapeutics of neurodegenerative diseases." Journal of Molecular Neuroscience. PMID:17628681